Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4CMenB gonorrhoea immune response study
ACTRN12623000738628Phase 3Recruiting
- Sponsor
- Griffith University
- Start
- Jun 2025
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of meningococcal group B vaccine in gonorrhea, sponsored by Griffith University. Primary endpoints: Serum bactericidal activity against Neisseria gonorrhoeae, Blocking of gonococcal adherence and invasion and 1 more. Started Jun 2025; status: recruiting.
02
Drugs
meningococcal group B vaccine
03
Conditions
gonorrhea
Beyond the preview
Go deeper on ACTRN12623000738628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000738628.